Rory B.  Riggs net worth and biography

Rory Riggs Biography and Net Worth

Mr. Riggs has served on our board of directors since January 2014. Mr. Riggs co-founded Royalty Pharma, an investment company focused on drug royalties, in 1996 and has served as Chairman of its investment committee since July 2003. Since April 2010, Mr. Riggs has served as founder and Chief Executive Officer of Syntax Analytics, LLC, a development stage venture focused on creating a new information technology platform for large-scale portfolio management. Since June 2006, Mr. Riggs has also served as Managing Member of New Ventures, a venture fund focused on healthcare. Since January 2001, Mr. Riggs has served as Managing Member of Balfour LLC, an investment management company focused on healthcare, biotechnology and technology. From 1996 until 2000, Mr. Riggs served as President and as a director of Biomatrix, Inc., a publicly-traded biopharmaceutical company. From 1991 to 1995, Mr. Riggs served as President and Chief Executive Officer of RF&P Corporation, an investment company owned by the State of Virginia Retirement System. Prior to that, he served as a managing director in PaineWebber's mergers and acquisitions department from 1981 to 1990. In addition to Royalty Pharma, Mr. Riggs serves on the board of directors of FibroGen, Inc. (since September 1993), a private biotechnology company; Cibus, LLC (since November 2001), a private agricultural technology company; GeneNews (since January 1998), a publicly-traded molecular diagnostic company; and eReceivables (since September 2003), a private healthcare service technology company. Mr. Riggs graduated from Middlebury College and holds an MBA from Columbia University.

What is Rory B. Riggs' net worth?

The estimated net worth of Rory B. Riggs is at least $9.73 million as of June 24th, 2024. Mr. Riggs owns 116,600 shares of Intra-Cellular Therapies stock worth more than $9,730,270 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Riggs may own. Learn More about Rory B. Riggs' net worth.

How do I contact Rory B. Riggs?

The corporate mailing address for Mr. Riggs and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Rory B. Riggs' contact information.

Has Rory B. Riggs been buying or selling shares of Intra-Cellular Therapies?

Rory B. Riggs has not been actively trading shares of Intra-Cellular Therapies over the course of the past ninety days. Most recently, Rory B. Riggs sold 4,462 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $75.57, for a transaction totalling $337,193.34. Following the completion of the sale, the director now directly owns 116,600 shares of the company's stock, valued at $8,811,462. Learn More on Rory B. Riggs' trading history.

Who are Intra-Cellular Therapies' active insiders?

Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.

Are insiders buying or selling shares of Intra-Cellular Therapies?

During the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 697,694 shares worth more than $49,905,719.27. The most recent insider tranaction occured on December, 4th when CEO Sharon Mates sold 51,000 shares worth more than $4,375,800.00. Insiders at Intra-Cellular Therapies own 2.6% of the company. Learn More about insider trades at Intra-Cellular Therapies.

Information on this page was last updated on 12/4/2024.

Rory B. Riggs Insider Trading History at Intra-Cellular Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/24/2024Sell4,462$75.57$337,193.34116,600View SEC Filing Icon  
3/18/2022Sell20,637$61.18$1,262,571.66View SEC Filing Icon  
3/16/2022Sell64,534$59.27$3,824,930.18View SEC Filing Icon  
See Full Table

Rory B. Riggs Buying and Selling Activity at Intra-Cellular Therapies

This chart shows Rory B Riggs's buying and selling at Intra-Cellular Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $83.45
Low: $82.76
High: $85.03

50 Day Range

MA: $83.64
Low: $73.84
High: $91.57

2 Week Range

Now: $83.45
Low: $62.78
High: $93.45

Volume

1,120,463 shs

Average Volume

827,488 shs

Market Capitalization

$8.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95